ClinConnect ClinConnect Logo
Search / Trial NCT04451538

Nutritional Intervention and Outcomes in Elderly After Hip Fracture Surgery

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jun 26, 2020

Trial Information

Current as of July 23, 2025

Unknown status

Keywords

Elderly Patients Malnutrition Hip Fractures Nutritional Intervention Perioperative Outcomes Long Term Survival

ClinConnect Summary

This clinical trial is studying how giving nutritional support to elderly patients who are malnourished or at risk of malnutrition can affect their recovery after hip fracture surgery. Since hip fractures are common in older adults and often require surgery, the researchers want to find out if improving nutrition around the time of surgery can help reduce complications and improve survival rates in these patients.

To be eligible for this trial, participants need to be at least 70 years old, hospitalized with a hip fracture, and scheduled for surgery within 48 hours. They also must be identified as malnourished or at risk of malnutrition based on a simple assessment. Participants will receive nutritional support during their hospital stay and will be monitored for how well they recover. It's important to note that certain medical conditions or a history of specific illnesses may prevent someone from joining the study. This trial aims to enhance the care and outcomes for elderly individuals facing hip fracture surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥70 years old;
  • Hospitalized for hip fracture, scheduled to undergo hip-fracture surgery within 48 hours;
  • Classified as malnutrition or at risk of malnutrition according to the short form mini-nutrition assessment (MNA-SF);
  • Provide written informed consents.
  • Exclusion Criteria:
  • Pathological fracture;
  • History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis before surgery;
  • Unable to communicate due to coma, severe dementia, or language barrier;
  • Unable to eat due to any disease in the gastrointestinal system;
  • Severe hepatic dysfunction (Child-Pugh class C), renal failure (requirement of renal replacement therapy), respiratory failure (requirement of respiratory support), cardiac insufficiency (New York Heart Association classification ≥IV), or American Socisty of Anesthesiologists classification ≥IV;
  • Preexisting organ injury before surgery (delirium, acute kidney injury, myocardial injury, etc.);
  • Other conditions that are considered unsuitable for study participation.

About Peking University First Hospital

Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.

Locations

Beijing, Beijing, China

Beijing, Beijing, China

Tianjin, Tianjin, China

Patients applied

0 patients applied

Trial Officials

Dong-Xin Wang, MD, PhD

Principal Investigator

Peking University First Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials